Skip to content

US · XTLB · BIOTECHNOLOGY

XTL Biopharmaceuticals Ltd. (XTLB) intrinsic value and stock valuation

$1.37as of 2026-11-21 · Mkt cap 2.7M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

XTL Biopharmaceuticals Ltd. DCF and intrinsic value

InvestorsCraft values XTLB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from XTLB’s statements →

XTL Biopharmaceuticals Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Ramat Gan, TA 5218102 xtlbio.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-6.97M
20112025
Free cash flow
-$-1.02M
20112025
Total equity
-$-250K
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$450K$0.00$0.00$0.00
Operating income-$-1.69M-$-2.17M-$-770K-$-880K-$-1.03M
Net income-$-6.97M-$-1.03M-$0.00-$-1.35M$430K
EPSd-$-15.84M-$-2.34M-$0.00-$-3.97M$1.13M
Operating cash flow-$-1.02M-$-1.62M-$-710K-$-900K-$-1.05M
Capital expenditure$0.00-$-50K$0.00$0.00$0.00
Free cash flow-$-1.02M-$-1.67M-$-710K-$-900K-$-1.05M
Total assets$170K$8.55M$2.43M$4.19M$6.62M
Total debt$270K$140K$0.00$0.00$0.00
Net debt$190K-$-230K-$-1.4M-$-2.09M-$-2.97M
Total equity-$-250K$5.43M$2.22M$4M$5.33M
Cash and short-term investments$140K$1.14M$2.01M$3.72M$6.13M
Income statement
20252024202320222021
Revenue$0.00$450K$0.00$0.00$0.00
Cost of revenue$0.00$450K$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00-$0.00-$0.00
Research and development expenses$30K$100K$30K$30K$30K
Selling, general and administrative expenses$1.13M$2.05M$730K$850K$1M
Other expenses$530K$30K$0.00$0.00$0.00
Operating expenses$1.69M$2.17M$770K$880K$1.03M
Cost and expenses$1.69M$2.62M$770K$880K$1.03M
Interest income$60K$30K$40K$40K$10K
Interest expense$10K$90K$0.00$10K$20K
Depreciation and amortization$0.00$200K$0.00$0.00$0.00
Ebitda-$-750K-$-930K-$-760K-$-880K-$-1.03M
Operating income-$-1.69M-$-2.17M-$-770K-$-880K-$-1.03M
Total other income/expenses, net$930K$1.01M-$-1.02M-$-470K$1.47M
Income before tax-$-760K-$-1.16M-$-1.78M-$-1.35M$430K
Income tax expense$0.00-$-130K$0.00$0.00$0.00
Net income-$-6.97M-$-1.03M-$0.00-$-1.35M$430K
Weighted average shares outstanding$420K$420K$340K$340K$330K
Weighted average diluted shares outstanding$440K$440K$340K$340K$380K
Balance sheet
20252024202320222021
Cash and short-term investments$140K$1.14M$2.01M$3.72M$6.13M
Net receivables$0.00$100K$30K$70K$90K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$170K$1.34M$2.05M$3.81M$6.24M
Property, plant and equipment, net$0.00$190K$0.00$0.00$0.00
Goodwill and intangible assets$0.00$7.01M$380K$380K$380K
Long-term investments$0.00$10K$0.00$0.00$0.00
Total non-current assets$0.00$7.21M$380K$380K$380K
Total assets$170K$8.55M$2.43M$4.19M$6.62M
Accounts payable$20K$200K$0.00$0.00$0.00
Short-term debt$270K$140K$0.00$0.00$0.00
Deferred revenue$0.00$20K$0.00$0.00$0.00
Total current liabilities$420K$2.21M$210K$190K$230K
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$910K$0.00$0.00$1.05M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$420K$3.12M$210K$190K$1.28M
Common stock$25.1M$23.1M$14.1M$14.1M$14.1M
Retained earnings-$-165.63M-$-159.01M-$-158.25M-$-156.47M-$-155.13M
Accumulated other comprehensive income (loss)$20K$20K$20K$20K$20K
Total equity-$-250K$5.43M$2.22M$4M$5.33M
Total investments$70K$790K$600K$1.63M$3.16M
Total debt$270K$140K$0.00$0.00$0.00
Net debt$190K-$-230K-$-1.4M-$-2.09M-$-2.97M
Cash flow statement
20252024202320222021
Net income-$-6.97M-$-1.03M-$-1.78M-$-1.35M$430K
Depreciation and amortization$0.00$200K$0.00$0.00$0.00
Stock-based compensation$350K$260K$0.00$10K$40K
Change in working capital-$0.00$190K$60K-$-20K-$-50K
Accounts receivable$160K$40K$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-190K$210K$20K-$-40K-$-20K
Net cash provided by operating activities-$-1.02M-$-1.62M-$-710K-$-900K-$-1.05M
Investments in property, plant and equipment$0.00-$-50K$0.00$0.00$0.00
Acquisitions, net-$-10K-$-410K$0.00$0.00$0.00
Net cash used for investing activities$520K-$-840K$40K$40K$10K
Common stock issued$0.00$1.46M$0.00$0.00$390K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$210K$1.45M$0.00$0.00$390K
Net change in cash-$-290K-$-1.03M-$-690K-$-880K-$-660K
Cash at end of period$80K$370K$1.4M$2.09M$2.97M
Operating cash flow-$-1.02M-$-1.62M-$-710K-$-900K-$-1.05M
Capital expenditure$0.00-$-50K$0.00$0.00$0.00
Free cash flow-$-1.02M-$-1.67M-$-710K-$-900K-$-1.05M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About XTL Biopharmaceuticals Ltd.

        XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.

        CEO
        Noam Band
        Employees
        10
        Beta
        0.46

        Explore

        Frequently asked questions

        What is the intrinsic value of XTL Biopharmaceuticals Ltd. (XTLB)?

        InvestorsCraft does not currently publish an intrinsic value for XTLB. How the IC value is calculated.

        Is XTLB undervalued?

        InvestorsCraft does not publish an undervaluation signal for XTLB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.